Table 1 Liquid biopsy assays currently in use for screening, diagnosis, and prognosis of Colorectal Cancer
From: Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer
Test Name (Ref) | Sample | Biomarker detected | Technology | Application |
|---|---|---|---|---|
Epi proColon [9] | Plasma | SEPT9 methylation | Bisulfite converted DNA and PCR | Screening |
OncoBEAM [10] | Plasma | 34 RAS mutations- 16 mutations in KRAS codons 12, 13, 59, 61, 117, 146 and 18 mutations in NRAS codons 12, 13, 59, 61, 117, 146 | Emulsion digital PCR with flow cytometry | Diagnostic |
Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay [11] | Plasma | 18 mutations in NRAS exons 2,3,4 5 mutations in BRAF codon 600 2 mutations in EGFR codon 492 | PCR | Diagnostic |
AdnaTest ColonCancerSelect and AdnaTest ColonCancerDetect [12] | Blood | Colon-cancer-associated gene expression of GA733-2, CEA and EGFR | PCR | Diagnostic |
Guardant360 [13] | Plasma | Tumour mutation profiling (73 genes) | NGS | Diagnostic |
TruSight Oncology 500 portfolio [14] | Blood | pan-cancer comprehensive genomic profiling of Single nucleotide variants (SNVs), Indels, CNVs, fusions, and IO biomarkers (TMB, MSI) | NGS | Diagnostic |
CellSearch [15] | Blood | CTC with CD45-, EpCAM + and (CK8, 18 and/or 19) | CTC immuno-isolation and detection by immune-fluorescence | Prognostic |
Intplex [16] | Plasma | KRAS/NRAS/BRAF point mutations | PCR | Prognosis Treatment selection |